Artificial intelligence is poised to transform drug discovery by analyzing vast datasets and predicting drug behavior, but significant challenges such as data quality, regulatory hurdles, and the complexity of biological systems must be addressed to fully realize its potential. Insitro, an AI-focused company, exemplifies this shift by leveraging machine learning to accelerate drug development, aiming to reduce costs and improve success rates in bringing new therapies to market.